DE602006007122D1 - Arginindeiminase enthaltende erythrozyten - Google Patents

Arginindeiminase enthaltende erythrozyten

Info

Publication number
DE602006007122D1
DE602006007122D1 DE602006007122T DE602006007122T DE602006007122D1 DE 602006007122 D1 DE602006007122 D1 DE 602006007122D1 DE 602006007122 T DE602006007122 T DE 602006007122T DE 602006007122 T DE602006007122 T DE 602006007122T DE 602006007122 D1 DE602006007122 D1 DE 602006007122D1
Authority
DE
Germany
Prior art keywords
arginineiminase
containing erythrocytes
arginine deiminase
erythrocytes
containing arginine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602006007122T
Other languages
English (en)
Inventor
Yann Godfrin
Pierre-Olivier Goineau
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Phaxiam Therapeutics SA
Original Assignee
Erytech Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Erytech Pharma SA filed Critical Erytech Pharma SA
Publication of DE602006007122D1 publication Critical patent/DE602006007122D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/18—Erythrocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/03—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amidines (3.5.3)
    • C12Y305/03006—Arginine deiminase (3.5.3.6)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE602006007122T 2005-04-25 2006-04-25 Arginindeiminase enthaltende erythrozyten Active DE602006007122D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0504122A FR2884717B1 (fr) 2005-04-25 2005-04-25 Erythrocytes renfermant de l'arginine deiminase
PCT/IB2006/001004 WO2006114691A1 (en) 2005-04-25 2006-04-25 Erythrocytes containing arginine deiminase

Publications (1)

Publication Number Publication Date
DE602006007122D1 true DE602006007122D1 (de) 2009-07-16

Family

ID=35787979

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602006007122T Active DE602006007122D1 (de) 2005-04-25 2006-04-25 Arginindeiminase enthaltende erythrozyten

Country Status (18)

Country Link
US (2) US9125876B2 (de)
EP (1) EP1874341B1 (de)
JP (1) JP5339899B2 (de)
KR (1) KR101431650B1 (de)
CN (1) CN101163497B (de)
AT (1) ATE432711T1 (de)
AU (1) AU2006238917C1 (de)
CA (1) CA2606420C (de)
CY (1) CY1109353T1 (de)
DE (1) DE602006007122D1 (de)
DK (1) DK1874341T3 (de)
ES (1) ES2326549T3 (de)
FR (1) FR2884717B1 (de)
HK (1) HK1112187A1 (de)
PL (1) PL1874341T3 (de)
PT (1) PT1874341E (de)
SI (1) SI1874341T1 (de)
WO (1) WO2006114691A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2919804B1 (fr) 2007-08-08 2010-08-27 Erytech Pharma Composition et vaccin therapeutique anti-tumoral
WO2009101467A1 (en) * 2008-02-13 2009-08-20 Erytech Pharma Formulation and method for the prevention and treatment of skeletal manifestation of gaucher's disease
WO2010023195A2 (en) * 2008-08-26 2010-03-04 Kyon Biotech Ag Compositions and methods for treating cancer
FR2940087B1 (fr) 2008-12-18 2011-05-06 Lab Francais Du Fractionnement Erythrocytes contenant du facteur viii, preparation et utilisations.
US9517257B2 (en) 2010-08-10 2016-12-13 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
CN103282380B (zh) 2010-08-10 2018-02-16 洛桑聚合联合学院 红细胞结合性治疗剂
US9850296B2 (en) 2010-08-10 2017-12-26 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
US9033948B2 (en) * 2011-04-19 2015-05-19 Fenwel, Inc. Single collection bag blood collection system, method and apparatus
FR3005420B1 (fr) 2013-05-07 2015-09-18 Erytech Pharma Procede de stabilisation de suspensions d'erythrocytes encapsulant un principe actif, suspensions obtenues.
CA2930665A1 (en) 2013-11-18 2015-05-21 Rubius Therapeutics, Inc. Synthetic membrane-receiver complexes
FR3017299B1 (fr) * 2014-02-12 2018-05-18 Erytech Pharma Composition pharmaceutique comprenant des erythrocytes encapsulant une enzyme a plp et son cofacteur
US10046056B2 (en) 2014-02-21 2018-08-14 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
EP3909603A1 (de) 2014-02-21 2021-11-17 Ecole Polytechnique Fédérale de Lausanne (EPFL) Glycotargeting-therapeutika
US10946079B2 (en) 2014-02-21 2021-03-16 Ecole Polytechnique Federale De Lausanne Glycotargeting therapeutics
US10953101B2 (en) 2014-02-21 2021-03-23 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
EP3583946A1 (de) 2014-04-01 2019-12-25 Rubius Therapeutics, Inc. Enucleated hematopoietic zellen enthaltend einen exogenen antigenes
EP3344575B1 (de) 2015-09-04 2020-04-15 SQZ Biotechnologies Company Intrazelluläres einbringen von biomolekülen in zellen mit einer zellwand
SG10202007639SA (en) 2016-01-11 2020-09-29 Rubius Therapeutics Inc Compositions and methods related to multimodal therapeutic cell systems for immune indications
EP3638296A1 (de) 2017-06-16 2020-04-22 The University Of Chicago Zusammensetzungen und verfahren zur herbeiführung einer immuntoleranz
EP3449935A1 (de) * 2017-08-31 2019-03-06 Erytech Pharma In erythrozyten eingekapselte arginin-deiminase und deren verwendung zur behandlung von krebs und arginase-1-mangel
WO2019042628A1 (en) 2017-08-31 2019-03-07 Erytech Pharma ARGININE DEIMINASE ENCAPSULATED WITHIN ERYTHROCYTES AND THEIR USE IN THE TREATMENT OF CANCER AND ARGINASE-1 DEFICIENCY
WO2020009740A2 (en) * 2018-04-25 2020-01-09 Washington University Compositions and methods of use thereof for treatment of metabolic diseases and related disorders
US11541105B2 (en) 2018-06-01 2023-01-03 The Research Foundation For The State University Of New York Compositions and methods for disrupting biofilm formation and maintenance
EP4149440A1 (de) 2020-05-11 2023-03-22 Erytech Pharma Erythrozyten-extrazellularvesikel (rbevs) mit frachten sowie verfahren zur verwendung und herstellung davon
CN113750232B (zh) * 2021-09-12 2023-06-02 重庆医科大学 一种巨噬细胞膜包覆精氨酸脱亚胺酶/过氧化氢酶/ir780纳米粒、制备方法和应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1051382A (de) * 1900-01-01
DE2740053A1 (de) * 1977-09-06 1979-05-03 Klaus Prof Dr Med Gersonde Verwendung von allosterischen effektoren mit hilfe von lipidvesikeln ueber eine irreversible inkorporierung zwecks verbesserter o tief 2 -entladung des haemoglobins in erythrozyten
JPH0235081A (ja) 1988-07-26 1990-02-05 Agency Of Ind Science & Technol アルギニン・デイミナーゼおよびその用途
JPH0253490A (ja) 1988-08-16 1990-02-22 Agency Of Ind Science & Technol アルギニン・デイミナーゼ遺伝子
EP0361150B1 (de) 1988-09-30 1994-12-14 Siemens Aktiengesellschaft Verfahren zum synchronisierten Umtasten eines Polarisationszustandes eines optischen Sendesignals eines optischen Übertragungssystems mit Überlagerungsempfang und Vorrichtung zur Durchführung des Verfahrens
JP2900279B2 (ja) 1989-08-02 1999-06-02 株式会社ジャパンエナジー 新規なアルギニンデイミナーゼ、その製造法及び該酵素を有効成分とする制癌剤
FR2678512B1 (fr) * 1991-07-03 1995-06-30 Novacell Machine a internaliser.
JP3004788B2 (ja) 1991-10-28 2000-01-31 株式会社ジャパンエナジー アルギニンデイミナーゼ発現ベクター、形質転換微生物およびアルギニンデイミナーゼの製造法
US5372942A (en) 1992-02-10 1994-12-13 Coriell Institute For Medical Research Protease K resistant arginine deiminase, its method of preparation and its use as an anti-neoplastic agent
US5612207A (en) * 1993-03-23 1997-03-18 Cbr Laboratories, Inc. Method and apparatus for encapsulation of biologically-active substances in cells
US5804183A (en) 1997-01-31 1998-09-08 Enzon, Inc. Arginine deminase derived from mycoplasma arthritidis and polymer conjugates containing the same
US6482585B2 (en) * 1997-04-16 2002-11-19 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Storage and maintenance of blood products including red blood cells and platelets
US6183738B1 (en) 1997-05-12 2001-02-06 Phoenix Pharamacologics, Inc. Modified arginine deiminase
KR100406268B1 (ko) 1999-12-24 2003-11-19 주식회사 안지오랩 아르기닌 디이미네이즈를 유효성분으로 하는 혈관신생에 의한 질환 치료용 조성물
AU2001275810A1 (en) 2000-07-27 2002-02-13 Angiolab, Inc. The pharmaceutical composition comprising arginine deiminase for inhibiting angiogenesis
JP2004515232A (ja) * 2000-11-28 2004-05-27 フエニツクス・フアーマコロジクス・インコーポレーテツド 修飾されたアルギニンデイミナーゼ
US7204980B2 (en) * 2002-11-18 2007-04-17 Phoenix Pharmacologics, Inc. Methods for inhibiting viral replication in vivo
US20070105220A1 (en) * 2003-08-06 2007-05-10 The Regents Of The University Of California Erythrocytic cells and method for loading solutes

Also Published As

Publication number Publication date
CN101163497A (zh) 2008-04-16
JP2008538761A (ja) 2008-11-06
EP1874341A1 (de) 2008-01-09
SI1874341T1 (sl) 2009-08-31
ATE432711T1 (de) 2009-06-15
US9125876B2 (en) 2015-09-08
AU2006238917A1 (en) 2006-11-02
US20160030532A1 (en) 2016-02-04
EP1874341B1 (de) 2009-06-03
ES2326549T3 (es) 2009-10-14
US20080274092A1 (en) 2008-11-06
PT1874341E (pt) 2009-07-21
AU2006238917B2 (en) 2011-04-07
CY1109353T1 (el) 2014-07-02
PL1874341T3 (pl) 2009-12-31
CN101163497B (zh) 2012-12-19
CA2606420C (en) 2015-01-27
DK1874341T3 (da) 2009-08-03
FR2884717A1 (fr) 2006-10-27
FR2884717B1 (fr) 2009-07-03
CA2606420A1 (en) 2006-11-02
US9968663B2 (en) 2018-05-15
KR20080000678A (ko) 2008-01-02
JP5339899B2 (ja) 2013-11-13
WO2006114691A1 (en) 2006-11-02
HK1112187A1 (en) 2008-08-29
AU2006238917C1 (en) 2011-08-04
KR101431650B1 (ko) 2014-08-20

Similar Documents

Publication Publication Date Title
DE602006007122D1 (de) Arginindeiminase enthaltende erythrozyten
Forman et al. Redox signaling: thiol chemistry defines which reactive oxygen and nitrogen species can act as second messengers
ATE508190T1 (de) Mehrfachpromotor-expressionskassetten zurgleichzeitigen zuführung von rnai-agentien
Sengupta et al. Thioredoxin catalyzes the denitrosation of low-molecular mass and protein S-nitrosothiols
BRPI0508470A (pt) sistema de teste in vitro para prever toleráncia do paciente aos agentes terapêuticos
MX2009004320A (es) Inhibidores de serina proteasa tipo tripsina, y su preparacion y uso.
EA200900091A1 (ru) Новые показания к применению прямых ингибиторов тромбина в лечении сердечно-сосудистых заболеваний
AR051765A1 (es) Compuestos de moleculas conjugadas con una actividad reforzada de absorcion de celulas
EA200800357A1 (ru) Новые фармацевтические соединения
WO2006075095A3 (fr) Utilisation de derives de la purine comme inhibiteurs de la proteine hsp90 et pour le traitement du cancer
WO2008054534A3 (en) Screening systems utilizing rtp801
Poloznikov et al. HIF prolyl hydroxylase inhibitors for COVID-19 treatment: pros and cons
ATE485261T1 (de) Salicylsäurederivate
MY150745A (en) Isoserine derivatives for use as coagulation factor ixa inhibitors
CY1116840T1 (el) Χρηση 24-norudca
CY1118302T1 (el) Λωριδα χαρτιου για τον καθορισμο των ελαχιστων ανασταλτικων συγκεντρωσεων αντιβιοτικων
WO2008081094A3 (fr) Methode de mesure fonctionnelle de l'activite de la thrombomoduline plasmatique
Yu et al. Prodrugs of persulfides, sulfur dioxide, and carbon disulfide: important tools for studying sulfur signaling at various oxidation states
ATE509958T1 (de) Gegen cathepsin s gerichtete therapie
EA200870434A1 (ru) Аминопроизводные андростанов и андростенов как лекарственные средства против сердечно-сосудистых нарушений
EA200870058A1 (ru) Композиции, содержащие остеопонтин крупного рогатого скота, для улучшения процесса заживления ран
Mirali et al. The role of mitochondrial proteases in leukemic cells and leukemic stem cells
Wang et al. Carbonic anhydrase II does not regulate nitrite‐dependent nitric oxide formation and vasodilation
BRPI0515161A (pt) substratos enzimáticos derivados de fenoxazinona e seu uso como revelador na detecção de microorganismos com atividade de peptidase
Jiang et al. Arginase inhibition protects against hypoxia‑induced pulmonary arterial hypertension

Legal Events

Date Code Title Description
8364 No opposition during term of opposition